Lilly Saw Pandemic-Related Benefits In Q1, Expects Headwinds Long Term

 
• By Joseph Haas

The pharma saw a $250m revenue increase due to inventory stockpiling and early prescription renewals, but its therapies outside cancer and diabetes may suffer in the coming quarters due to COVID-19.

business documents accounting with calculator and magnifying glass. concept for financial
Lilly's strong first quarter benefited from pandemic-related stocking and early prescription renewals

More from Earnings

More from Business